ClinicalTrials.gg
TerminatedNCT07019129Updated Jun 12, 2026

Effects of Dietary Nitrate in Women With Secondary Amenorrhea

An interventional study of Beetroot Juice - Active and Placebo Beetroot Juice Without Nitrate in Secondary Amenorrhea, sponsored by Indiana University. Terminated at 1 site in United States. Open to female participants aged 18 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Indiana University · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Unable to recruit adequate number of participants

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Enrollment
24th of 30
3 · median 37
Started
2025
with 3 others
No phase
8 of 43
1 open now
Registered
41st of 43
by date

Among the 43 studies in Amenorrhea with a site in United States, this one is the 24th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 with no phase, and was the 41st registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 44 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

Excessive exercise, disordered attitudes toward eating, physical and psychological stress, and/or hormonal imbalances may result in cessation of menstruation (secondary amenorrhea). The accompanying lack of estrogen may impair muscle power and oxygen recovery after exercise by reducing nitric oxide levels. The purpose of this study is to determine whether ingestion of beetroot juice containing nitrate, an alternative source of nitric oxide, can help reverse these changes.

Read the detailed description

Due to excessive exercise, disordered attitudes toward eating, physical and psychological stress, and/or hormonal imbalances, young women may be predisposed to developing secondary amenorrhea. Secondary amenorrhea is defined as the absence of menses for at least 3 months in regularly menstruating women or at least 6 months in irregularly menstruating women [1]. This disorder of the hypothalamic-pituitary axis (HPO) is associated with a short-term lack of endogenous estradiol (E2), which may have negative health consequences [2-7]. For example, E2 plays an important role in regulating skeletal muscle mass and contractile function, including both strength and power [4]. In part, this is because E2 increases phosphorylation of the regulatory light chain of myosin, thereby enhancing muscle contractility [6, 8]. Lack of E2 also alters lipid and carbohydrate metabolism [9, 10], which may be due to the important role E2 plays in regulating mitochondrial function, more specifically respiration and efficiency. This impairment in metabolism and mitochondrial respiration could increase CVD risk and alter plasma levels of lipids, cortisol, and insulin [2, 9, 10]. Indeed, Ronkainen et al. [11] found that postmenopausal women not on hormone replacement therapy (HRT) have reduced skeletal muscle strength and power compared to those on HRT, whereas Kleis-Olsen et al. [12] reported similar findings with respect to fat mass and mitochondrial respiratory capacity. Younger women with secondary amenorrhea may also suffer from similar impairments due to E2 deficiency.

It has also been shown that short term lack of E2 compromises nitric oxide synthase (NOS) activity, which plays a critical role in cardiovascular health, exercise capacity, and vasomodulation and mitochondrial function within skeletal muscle [7, 13, 14]. Conversely, dietary nitrate supplementation can increase nitric oxide bioavailailbity, via an enterosalivary pathway in which nitrate is reduced to nitrite that in turn is further reduced to nitric oxide [15]. It has been demonstrated that dietary nitrate improves muscle contractility [16], exercise capacity and performance [15, 17], vascular function [18], and mitochondrial efficiency during exercise [5, 19, 20]. Indeed, we have found nitrate supplementation to be particularly effective in increasing muscular speed and power in postmenopausal women [21]. Increasing NO bioavailability via ingestion of nitrate therefore may have beneficial effects on both muscle function and mitochondrial function in women with secondary amenorrhea. To date, however, this hypothesis has not been tested.

Although the aforementioned research has highlighted the beneficial effects of dietary nitrate supplementation on muscle contractile function and mitochondrial respiration in various populations, no studies have examined the effects of this supplementation on these parameters in women with secondary amenorrhea. The proposed study will therefore provide a better understanding of the effects of dietary nitrate supplementation on muscle function and mitochondrial respiration in women with secondary amenorrhea, potentially improving health, recovery, and performance outcomes within this vulnerable population.

  1. Rebar, R., Evaluation of Amenorrhea, Anovulation, and Abnormal Bleeding, in Endotext, K.R. Feingold, et al., Editors. 2000: South Dartmouth (MA).
  2. Gupte, A.A., H.J. Pownall, and D.J. Hamilton, Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res, 2015. 2015: p. 916585.
  3. Ihalainen, J.K., et al., Beyond Menstrual Dysfunction: Does Altered Endocrine Function Caused by Problematic Low Energy Availability Impair Health and Sports Performance in Female Athletes? Sports Med, 2024. 54(9): p. 2267-2289.
  4. Chidi-Ogbolu, N. and K. Baar, Effect of Estrogen on Musculoskeletal Performance and Injury Risk. Front Physiol, 2018. 9: p. 1834.
  5. Larsen, F.J., et al., Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab, 2011. 13(2): p. 149-59.
  6. Lai, S., et al., Estradiol modulates myosin regulatory light chain phosphorylation and contractility in skeletal muscle of female mice. Am J Physiol Endocrinol Metab, 2016. 310(9): p. E724-33.
  7. O'Donnell, E. and M.J. De Souza, The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review. Sports Med, 2004. 34(9): p. 601-27.
  8. Greenberg, M.J., et al., The molecular effects of skeletal muscle myosin regulatory light chain phosphorylation. Am J Physiol Regul Integr Comp Physiol, 2009. 297(2): p. R265-74.
  9. An, J., et al., Sex- and endurance training-mediated cardiovascular protection through lipids during exercise. Trends Endocrinol Metab, 2024.
  10. Senoz, S., et al., Estrogen deprivation, rather than age, is responsible for the poor lipid profile and carbohydrate metabolism in women. Maturitas, 1996. 25(2): p. 107-14.
  11. Ronkainen, P.H., et al., Postmenopausal hormone replacement therapy modifies skeletal muscle composition and function: a study with monozygotic twin pairs. J Appl Physiol (1985), 2009. 107(1): p. 25-33.
  12. Kleis-Olsen, A.S., et al., Metabolic flexibility in postmenopausal women: Hormone replacement therapy is associated with higher mitochondrial content, respiratory capacity, and lower total fat mass. Acta Physiol (Oxf), 2024. 240(6): p. e14117.
  13. Fadel, P.J., W. Zhao, and G.D. Thomas, Impaired vasomodulation is associated with reduced neuronal nitric oxide synthase in skeletal muscle of ovariectomized rats. J Physiol, 2003. 549(Pt 1): p. 243-53.
  14. Tengan, C.H., G.S. Rodrigues, and R.O. Godinho, Nitric oxide in skeletal muscle: role on mitochondrial biogenesis and function. Int J Mol Sci, 2012. 13(12): p. 17160-84.
  15. Amdahl, M.B., A.W. DeMartino, and M.T. Gladwin, Inorganic nitrite bioactivation and role in physiological signaling and therapeutics. Biol Chem, 2019. 401(1): p. 201-211.
  16. Coggan, A.R. and L.R. Peterson, Dietary Nitrate Enhances the Contractile Properties of Human Skeletal Muscle. Exerc Sport Sci Rev, 2018. 46(4): p. 254-261.
  17. Flueck, J.L., et al., Is beetroot juice more effective than sodium nitrate? The effects of equimolar nitrate dosages of nitrate-rich beetroot juice and sodium nitrate on oxygen consumption during exercise. Appl Physiol Nutr Metab, 2016. 41(4): p. 421-9.
  18. Craig, J.C., et al., Effect of dietary nitrate supplementation on conduit artery blood flow, muscle oxygenation, and metabolic rate during handgrip exercise. J Appl Physiol (1985), 2018. 125(2): p. 254-262.
  19. Bailey, S.J., et al., Dietary nitrate supplementation enhances muscle contractile efficiency during knee-extensor exercise in humans. J Appl Physiol (1985), 2010. 109(1): p. 135-48.
  20. Pappas, G., M.L. Wilkinson, and A.J. Gow, Nitric oxide regulation of cellular metabolism: Adaptive tuning of cellular energy. Nitric Oxide, 2023. 131: p. 8-17.
  21. Coggan, A.R., et al., Dietary nitrate-induced increases in human muscle power: high versus low responders. Physiol Rep, 2018. 6(2).
  22. Jungersten, L., et al., Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol, 1996. 16(4): p. 369-79.
  23. Govoni, M., et al., The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide, 2008. 19(4): p. 333-7.
  24. Joint FAO/WHO Expert Committee on Food Additives. Meeting (61st: 2003, R., Italy) \& International Programme on Chemical Safety., Safety evaluation of certain food additives and contaminants/prepared by the sixty-first meeting of the Joint FAO/WHO Expert Committee on Food Additives (JEFCA). 2004.
  25. Goodman, J., S. Thomas, and J.F. Burr, Physical activity series: cardiovascular risks of physical activity in apparently healthy individuals: risk evaluation for exercise clearance and prescription. Can Fam Physician, 2013. 59(1): p. 46-9, e6-e10.
  26. Sumner, M.D., et al., Near Infrared Spectroscopy Measurements of Mitochondrial Capacity Using Partial Recovery Curves. Front Physiol, 2020. 11: p. 111.
  27. Gallardo EJ, Gray DA, Hoffman RL, Yates BA, Moorthi RN, Coggan AR. Dose-response effect of dietary nitrate on muscle contractility and blood pressure in older subjects: a pilot study. J Gerontol A Biol Sci Med Sci 2021; 76:591-598.
  28. Zoughaib WS, Hoffman RL, Yates BA, Moorthi RN, Lim K, Coggan AR. Short-term beetroot juice supplementation improves muscle contractility but does not reduce blood pressure or oxidative stress in 65-79 y old men and women. Nitric Oxide 20
03

Conditions studied

  • Secondary Amenorrhea

Browse trials for

Keywords

  • dietary nitrate
  • secondary amenorrhea
  • muscle function
04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women age 18-44 years old
  • Missed >3 consecutive periods in the last 12 months if previously regularly menstruating (average cycle 21-35 d) OR
  • Missed >6 consecutive periods in the last 12 month if previously irregularly menstruating (spontaneous menstruation, average cycle \<21 or > 35 d)

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Currently diagnosed with primary amenorrhea (no history of menstruation by age 15) or oligomenorrhea (menstrual cycle >35 d or \<8 cycles per year)
  • Currently diagnosed with a chronic illness, including thyroid disease, hyperprolactinemia, Cushing syndrome, and/or poly-cystic ovarian syndrome (PCOS)
  • History or current clinical diagnosis of an eating disorder
  • Currently dieting
  • Weight instablility for the past 3 months
  • Previously undergone a revascularization procedure involving a vascular graft or stenting of the femoral or popliteal arteries
  • Currently at the time of screening, or in the past year, using hormonal
  • Pregnancy
  • Epilepsy
  • Current antibiotic use
  • Current nicotine user
  • Stage II hypertension (resting blood pressure >140/>90)
  • Currently taking proton pump inhibitors, antacids, xanthine oxidase inhibitors, or on hormone replacement therapy
  • An answer of yes to any of the seven questions on the first page of the Physical Activity Readiness Questionnaire (PAR-Q) indicating that the participant is not physically ready for exercise without a medical exam. These exclusions include the following:
  • If participant's doctor has ever said that he/she has a heart condition and that he/she should only do physical activity recommended by a doctor
  • Pain in chest when doing physical activity
  • In past month, chest pain when not doing physical activity
  • If participant has ever lost balance because of dizziness or has ever lost consciousness
  • Muscle, bone, or joint problem that could be made worse by physical activity
  • Currently on prescribed drugs for blood pressure or heart condition.
  • If the participant knows of any other reason he/she should not do physical activity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
3 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Nitrate-free beetroot juice

    Dietary Supplement: Placebo Beetroot Juice Without Nitrate

  • Experimental
    Nitrate

    Nitrate-rich beetroot juice

    Dietary Supplement: Beetroot Juice - Active

Interventions

  • Dietary supplementBeetroot Juice - Active

    Nitrate-rich beetroot juice

  • Dietary supplementPlacebo Beetroot Juice Without Nitrate

    Nitrate-poor beetroot juice

06

What researchers measure

Primary outcomes

  1. Maximal knee extensor power

    Maximal power of the knee extensor (thigh) muscles as determined using isokinetic dynamometry

    Time frame: Approximately 2-3 hours after beetroot ingestion

  2. Muscle reoxygenation kinetics

    Recovery rate constant (k) of muscle oxygenation following exercise as determined using NIRS (near-infrared spectroscopy) combined with brief intermittent arterial occlusion

    Time frame: Approximately 2-3 hours after beetroot juice ingestion

Secondary outcomes

  1. Maximal knee extensor velocity

    Maximal velocity of the knee extensor (thigh) muscles as determined using isokinetic dynamometry

    Time frame: Approximately 2-3 hours after beetroot juice ingestion

  2. Deoxygenation rate

    Rate of deoxygenation of the knee extensor (thigh) muscles during 5 minutes of continuous arterial occlusion as determined using NIRS (near-infrared spectroscopy)

    Time frame: Approximately 2-3 hours after beetroot juice ingestion

  3. Reoxygenation rate

    Rate of reoxygenation of the knee extensor (thigh) muscles following 5 minutes of continuous arterial occlusion as determined using NIRS (near-infrared spectroscopy)

    Time frame: Approximately 2-3 hours after beetroot juice ingestion

Other outcomes

  1. Baseline plasma nitrate/nitrite concentration

    Concentrations of nitrate and nitrite in blood plasma as determined using HPLC (high performance liquid chromatography)

    Time frame: Before beetroot juice ingestion

  2. Plasma nitrate/nitrite concentration at 1 hour

    Concentrations of nitrate and nitrite in blood plasma as determined using HPLC (high performance liquid chromatography)

    Time frame: 1 hour after beetroot juice ingestion

  3. Plasma nitrate/nitrite concentration at 2 hours

    Concentrations of nitrate and nitrite in blood plasma as determined using HPLC (high performance liquid chromatography)

    Time frame: 2 hours after beetroot juice ingestion

  4. Plasma nitrate/nitrite concentration at 3 hours

    Concentrations of nitrate and nitrite in blood plasma as determined using HPLC (high performance liquid chromatography)

    Time frame: Approximately 3 hours after beetroot juice ingestion

  5. Estradiol concentration

    Concentration of estradiol (E2) in blood plasma as determined using ELISA (enzyme linked immunosorbent assay)

    Time frame: Before beetroot juice ingestion

  6. Follicle stimulating hormone concentration

    Concentration of follicle stimulating hormone (FSH) in blood plasma as determined using ELISA (enzyme linked immunosorbent assay)

    Time frame: Before beetroot juice ingestion

07

Study locations

1 site
  • Indiana University Indianapolis
    Indianapolis, Indiana 46202, United States
08

References and documents

Individual participant data

Plan to share: Yes — All non-PHI individual participant data will be shared upon reasonable request.

Time frame: Data will be made available upon completion of the study and publication of the final results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Apr 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Sep 5, 2025
Primary completionActual
Apr 2, 2026
CompletionActual
Apr 2, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019129
Lead sponsor
Indiana University
Responsible party
Andrew Coggan (Associate Professor, Indiana University) — Principal investigator
First posted
Jun 13, 2025
Start date
Sep 5, 2025
Primary completion
Apr 2, 2026
Completion
Apr 2, 2026
Last update
Jun 12, 2026

Study contacts

Andrew R Coggan, PhD
principal investigator · Indiana University Indianapolis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion